Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 190

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 190
---
 progression of glioblastoma until the earlier of the closing of the Merger or December 31, 2025. In addition, concurrently
with the execution of the Merger Agreement, DiamiR, DiamiR LLC, a wholly owned subsidiary of DiamiR, the Company and Aptorum Therapeutics
entered into an intellectual property license agreement (“Licensing Agreement”), pursuant to which DiamiR and DiamiR LLC shall
license on a non-exclusive basis their respective intellectual properties to Aptorum Therapeutics in exchange for upfront and periodic
payments and royalties until the earlier of the closing of the Merger or December 31, 2025. Ian Huen, Aptorum’s Chairman and Chief
Executive Officer, who beneficially owns approximately 87% of the Company’s total voting power, signed a voting and support agreement
simultaneously with the execution of the Merger Agreement, pursuant to which he agreed to vote in favor of the transactions contemplated
in the Merger Agreement. Upon closing, Aptorum and certain stockholders of DiamiR, who collectively own 84.9% of DiamiR’s outstanding
shares, will sign a stockholders agreement (“Stockholders Agreement”), which will be effective so long as the stockholders
of DiamiR beneficially own, in the aggregate, a number of shares of common stock of the Combined Company equal to at least 25% of the
then outstanding shares of the Combined Company (such beneficial ownership, the “DiamiR Stockholders Beneficial Ownership”;
such period, the “Appointment Period”). The parties agree that, during the Appointment Period, they will take all necessary
actions to cause the number of directors at the Board of the Combined Company to be fixed at five (5). In addition, Kira S. Sheinerman,
the co-founder and a stockholder of DiamiR, and her affiliates (“DiamiR Primary Stockholder Parties”) will have the right
to appoint two (2) designees (each designee, the “Primary Stockholder Designee”, collectively, the “Primary Stockholder
Designees”) for nomination and election to the Board of Combined Company, and at least one (1) designee shall satisfy the independence
requirements of Rule 5605(c)(2)(A) of the Nasdaq listing rules, provided that the DiamiR Stockholders Beneficial Ownership is not less
than 36%, and the DiamiR Primary Stockholder Parties will have the right to appoint one (1